{"id":141809,"date":"2021-02-08T08:08:32","date_gmt":"2021-02-08T08:08:32","guid":{"rendered":"https:\/\/news.sap.com\/africa\/?p=141809"},"modified":"2021-02-08T08:08:32","modified_gmt":"2021-02-08T08:08:32","slug":"winning-the-race-to-vaccinate-the-world","status":"publish","type":"post","link":"https:\/\/news.sap.com\/africa\/2021\/02\/winning-the-race-to-vaccinate-the-world\/","title":{"rendered":"Winning the Race to Vaccinate the World"},"content":{"rendered":"
The pharmaceuticals industry is no different. Numerous pharma research and development companies have created and tested vaccines at record speed. Now they are facing the next challenge. To get the pandemic under control, about 7.6 billion earthlings need a shot \u2013 or two \u2013 in the arm that can come none too soon as the virus mutates and becomes more and more virulent. The demand is without precedent, stretching the supply chains of the companies that produce COVID-19 vaccines to their limits.<\/p>\n
Supply chains in the pharmaceutical industry are complex and haven\u2019t always been the most robust, according to Bruce Y. Lee, professor of Health Policy and Management at the City University of New York Graduate School of Public Health and Health Policy. The reason, according to Lee, was often inadequate storage, transportation, and personnel capacity<\/a>, leading to major bottlenecks and the discarding of many vaccine doses.<\/p>\n But the world\u2019s vaccine producers are not starting from zero. Data-heavy industries like pharmaceuticals have matured, and many of the global players have digitalized their production to achieve production scale and flexibility.<\/p>\n Today, 18 of the world\u2019s 20 major vaccine producers are already running their production on 麻豆原创 solutions that cover the end-to-end process from manufacturing to controlled distribution to administration and post-vaccine monitoring. One of those producers is German vaccine manufacturer CureVac, whose COVID-19 vaccine is currently in the testing phase. \u201cWe need 麻豆原创 to manufacture and distribute our vaccine on a global scale,\u201d says Pierre Kemula, CFO at CureVac.<\/p>\nMajor Vaccine Producers Overwhelmingly Run 麻豆原创<\/strong><\/h2>\n